Amicus Therapeutics (FOLD) Stock Price, News & Analysis

+0.07 (+0.74%)
(As of 05/17/2024 ET)
Today's Range
50-Day Range
52-Week Range
2.15 million shs
Average Volume
3.00 million shs
Market Capitalization
$2.83 billion
P/E Ratio
Dividend Yield
Price Target

Amicus Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.86 Rating Score
82.9% Upside
$17.50 Price Target
Short Interest
9.71% of Shares Sold Short
Dividend Strength
Upright™ Environmental Score
News Sentiment
0.35mentions of Amicus Therapeutics in the last 14 days
Based on 13 Articles This Week
Insider Trading
Selling Shares
$176,025 Sold Last Quarter
Proj. Earnings Growth
From ($0.19) to $0.22 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.38 out of 5 stars

Medical Sector

122nd out of 923 stocks

Pharmaceutical Preparations Industry

45th out of 425 stocks

FOLD stock logo

About Amicus Therapeutics Stock (NASDAQ:FOLD)

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.

FOLD Stock Price History

FOLD Stock News Headlines

Evaluating Amicus Therapeutics: Insights From 6 Financial Analysts
Amicus Therapeutics: Q1 Earnings Snapshot
Amicus Therapeutics Inc.
Amicus Therapeutics Becomes Oversold (FOLD)
FOLD Jul 2024 12.000 call
FOLD Oct 2024 12.000 call
FOLD Jan 2025 12.000 put
See More Headlines
Receive FOLD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Amicus Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
7 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
$399.36 million
Book Value
$0.44 per share


Free Float
Market Cap
$2.83 billion

Social Links

10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

FOLD Stock Analysis - Frequently Asked Questions

Should I buy or sell Amicus Therapeutics stock right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amicus Therapeutics in the last twelve months. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" FOLD shares.
View FOLD analyst ratings
or view top-rated stocks.

What is Amicus Therapeutics' stock price target for 2024?

7 brokerages have issued 12 month price targets for Amicus Therapeutics' shares. Their FOLD share price targets range from $13.00 to $22.00. On average, they expect the company's stock price to reach $17.50 in the next twelve months. This suggests a possible upside of 82.9% from the stock's current price.
View analysts price targets for FOLD
or view top-rated stocks among Wall Street analysts.

How have FOLD shares performed in 2024?

Amicus Therapeutics' stock was trading at $14.19 at the beginning of the year. Since then, FOLD shares have decreased by 32.6% and is now trading at $9.57.
View the best growth stocks for 2024 here

When is Amicus Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024.
View our FOLD earnings forecast

How were Amicus Therapeutics' earnings last quarter?

Amicus Therapeutics, Inc. (NASDAQ:FOLD) issued its quarterly earnings results on Thursday, May, 9th. The biopharmaceutical company reported ($0.02) EPS for the quarter, topping the consensus estimate of ($0.06) by $0.04. The biopharmaceutical company earned $110.40 million during the quarter, compared to analysts' expectations of $111.19 million. Amicus Therapeutics had a negative net margin of 34.73% and a negative trailing twelve-month return on equity of 77.08%. Amicus Therapeutics's revenue was up 27.9% on a year-over-year basis. During the same period in the previous year, the business earned ($0.18) earnings per share.

What guidance has Amicus Therapeutics issued on next quarter's earnings?

Amicus Therapeutics issued an update on its FY 2024 earnings guidance on Thursday, May, 9th. The company provided EPS guidance of for the period. The company issued revenue guidance of $499.2 million-$519.2 million, compared to the consensus revenue estimate of $530.0 million.

What is John F. Crowley's approval rating as Amicus Therapeutics' CEO?

21 employees have rated Amicus Therapeutics Chief Executive Officer John F. Crowley on John F. Crowley has an approval rating of 48% among the company's employees. This puts John F. Crowley in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Amicus Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amicus Therapeutics investors own include NVIDIA (NVDA), AcelRx Pharmaceuticals (ACRX), Gilead Sciences (GILD), Sangamo Therapeutics (SGMO), Sarepta Therapeutics (SRPT), AbbVie (ABBV), Exelixis (EXEL), Advanced Micro Devices (AMD), Inovio Pharmaceuticals (INO) and Novavax (NVAX).

Who are Amicus Therapeutics' major shareholders?

Amicus Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (9.52%), Janus Henderson Group PLC (4.66%), Redmile Group LLC (4.48%), William Blair Investment Management LLC (3.89%), Healthcare of Ontario Pension Plan Trust Fund (0.73%) and Price T Rowe Associates Inc. MD (0.47%). Insiders that own company stock include Bradley L Campbell, Burke W Whitman, Burke W Whitman, Daphne Quimi, David Michael Clark, Ellen Rosenberg, Ellen Rosenberg, Jeff Castelli, John F Crowley, John F Crowley, Lynn Dorsey Bleil, Margaret G Mcglynn, Michael Raab and Samantha Prout.
View institutional ownership trends

How do I buy shares of Amicus Therapeutics?

Shares of FOLD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:FOLD) was last updated on 5/18/2024 by Staff

From Our Partners